Case Study: Taimei’s IWRS system meets increasingly common and complex blind designs​

Blinding is an important measure to control trial bias in clinical trials, and blindness maintenance is also the most basic requirement for randomized systems. However, in a trial, different stages and different drugs may have different blinding requirements. If the system only follows the fully blinded design regardless of the different requirements of the experimental program is not the best practice. At present, the number of blind projects implemented by Taimei Technology accounts for about 80% of the total, and more open trials are also being built according to the blind settings of the blind trials.

Read More

Does AI/ML make CROs obsolete? It depends…

The CRO industry has a choice to make: their leaders can retire to a plantation, as the famous pirate Henry Morgan did, or they can adapt their model to one that is technology driven and cost-efficient, leveraging it to deliver clinical trials, says Taimei’s Scott Clark.

Read More

Why data management and decision-making go hand-in-hand in clinical research

The pharmaceutical industry is fuelled by data. Huge amounts of information are available from sources as diverse as patient health records, wearables, and social media content. If sponsors can harness it, this data can provide the key to saving time, labour and costs across the pharmaceutical value chain, ultimately bringing better drug products to patients sooner.

Read More

How automating clinical trial payments can Unlock end-to-end efficiencies

Traditional approaches to payment management for clinical trials are highly manual, labour-intensive, and subject to human error. In an industry where timelines are critical and accuracy is paramount, sponsors seek a better way to negotiate, track and reconcile trial payments. Automation takes away the manual burden while offering new levels of speed and accuracy.

Read More

Taimei Technology opens Singapore office to support digital transformation of clinical research in APAC

China-based Taimei Technology, a digital cooperation platform for the life science industry, announced the opening of its new office in Singapore on February 1, 2023. The office, strategically located in one of the world’s financial centres as well as one of APAC’s economic and cultural centres, is expected to help accelerate the adoption of the company’s innovative digital technologies for clinical research across the region and provide local customers with better services and experience with the support of local resources, while working with Taimei’s partners to improve the application of digital technologies in regional clinical research and empower pharmaceutical innovations.

Read More